EN DE
Watch CORDLIFE GROUP LIMITED for free: we tell you when fair value or trend changes.
Data-driven stock valuation

CORDLIFE GROUP LIMITED (P8A) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of CORDLIFE GROUP LIMITED stock S$0.11, price S$0.09, upside +17.2%, quality 47 out of 100. Rating: fairly valued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare SG · ISIN SG2E64980112

CG CORDLIFE GROUP LIMITED logo Thin data Nov 15, 2026

CORDLIFE GROUP LIMITED

P8A · SG

The stock is already about fairly priced, weak company and falling price: meets none of the 3 rules.

Get notified free when this changes
Low debt 
Fair value 0.1067 SGD · Fairly valued 
Quality 47/100 
Revenue last quarter 14% below a year ago. 
Falling price (downtrend) 
Weak Growth (revenue 5y −5.2 %/yr in SGD) 
Loss-making · -28.9% net margin (TTM) 
Negative free cash flow 
Trails peers (4/11) 
Narrow moat 8/100 · thin data
Thin data 
Estimate⚠ Thinly traded
Watch CORDLIFE GROUP LIMITED for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

0.5550 SGD 0.0910 SGD Fair Value 0.1067 SGD Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 15, 2026.

How to read this chart

60‑month range 0.0910 SGD – 0.5550 SGD · fair‑value band 0.0821 SGD – 0.1313 SGD · the 0.0910 SGD price screens below the 0.1067 SGD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 15, 2026.

Follow CORDLIFE GROUP in your weekly email

Every Wednesday you see whether CORDLIFE GROUP is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Cordlife GrouCordlife Group Limited, an investment holding company, provides cord blood banking services in Singapore, Hong Kong, India, Malaysia, the Philippines, and internationally. It operates in two segments, Banking and Diagnostics.

Show moreShow less

The Banking segment collects, processes, banks, and tests biological materials, such as cord blood, lining, and tissue samples.

The Diagnostics segment offers diagnostic testing services, such as newborn genetic and metabolic screenings; pediatric vision and ear screenings; pediatric allergen test; and genetic talent test services.

The company also provides corneal lenticule banking, and lifestyle genetic screening services for adults. In addition, it offers life sprouts, medical laboratory, marketing, and property investment services, as well as medical and pharmaceutical research and development and consulting services.

Cordlife Group Limited was incorporated in 2001 and is based in Singapore.

Stock analysis

CORDLIFE GROUP LIMITED (P8A) currently trades at 0.0910 SGD, while our estimate is 0.1067 SGD, so the stock looks roughly fairly valued today (gap 14.7%).

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: 0.0821 SGD (bear) to 0.1313 SGD (bull), the price of 0.0910 SGD sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 47/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

CORDLIFE GROUP LIMITED reported revenue of 38.9M SGD in FY2025 versus 56.7M SGD in FY2021, a compound −9.0%/yr. Reported net income was −12.6M SGD in FY2025.

Key figures

Market cap 23.3M SGD (≈ $18.1M) Micro · P/S ratio 0.64 · EPS (TTM) −0.0400 SGD · Dividend yield 0.3% · Net margin −28.9% · Return on equity −10.1% · Return on assets (EBIT) −3.3% (5-year average) · Operating margin −18.1%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 8 out of 100 (low confidence).

What moves the price

The share trades about 52% below its 52-week high and at its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −10% fair-value upside, at 17%, P8A screens cheaper than that median.

Fair Value

Bear 0.0821 SGD Fair Value 0.1067 SGD Bull 0.1313 SGD
Price 0.0910 SGD · Upside +17.2%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 47/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 5
How much profit the company makes from its sales and capital
Quality Growth 91
Are margins and returns getting better?
Cashflow 6
Do the profits arrive as real cash?
Financial strength 50
Debt, balance sheet and risk of trouble
Investment 97
Does it invest with discipline instead of growing at any price?
Low Volatility 43
How calm the share price moves, does not count
Price momentum 10
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 0
Distance to the 52-week high, does not count
New shares 82
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 6/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+40.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−11.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−5.2%
Start year 2020 (pandemic). Over 10 years: −4.2% a year
Revenue growth 12 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−1.9%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
14.6% (2020) → −38.2% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Watch P8A, get fair value alerts →

Compare CORDLIFE GROUP LIMITED with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Diagnostics & Research · 150 stocks

Beats the industry median on 3/9 measures
Overall it trails its industry peers.
Valuation
Quality Score 47 · Below median
Fair Value upside +17.3% · Top 25%
Profitability
Return on assets −6.3% · Below median
Net margin (12 months) −28.9% · Bottom 25%
Operating margin (12 months) −18.1% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) −13.6% · Bottom 25%
Dividend yield (12 months) 0.3% · Bottom 25%

Valuation Multiplesvs Diagnostics & Research median · lower = cheaper

P/B 0.22× · Cheapest 25%
P/S (12 months) 0.63× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)56 · sector 14
FUTURE (revenue growth)0 · sector 40
PAST (return on equity)0 · sector 8
HEALTH (low debt)100 · sector 95
DIVIDEND (yield)6 · sector 33

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
WuXi AppTec Co 603259 ¥144.41 ¥164.66 +14% vs P8A
IQVIA Holdings IQV $265.12 $291.63 +10% vs P8A
Illumina, Inc ILMN $207.01 $227.71 +10% vs P8A
Thermo Fisher Scientific Inc TMO $700.22 $686.04 −2% vs P8A
Danaher Corporation DHR $233.02 $209.18 −10% vs P8A
IDEXX Laboratories, Inc IDXX $704.23 $496.48 −30% vs P8A
Lonza Group LONN CHF 670.20 CHF 259.80 −61% vs P8A
Mettler-Toledo International Inc MTD $1,739 $655.06 −62% vs P8A
Agilent Technologies, Inc A $173.96 $64.53 −63% vs P8A
Waters Corporation WAT $460.25 $91.26 −80% vs P8A

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

CORDLIFE GROUP LIMITED: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "CORDLIFE GROUP LIMITED Fair Value". https://www.fairvalue-calculator.com/stock/P8A

Frequently asked questions

Is CORDLIFE GROUP LIMITED (P8A) overvalued or undervalued?
As of Nov 15, 2026, our estimate of fair value is 0.1067 SGD versus a price of 0.0910 SGD, about +17% upside (fairly valued).
What is the fair value of P8A?
Our estimate for CORDLIFE GROUP LIMITED is 0.1067 SGD (as of Nov 15, 2026), built from audited fundamentals. The current price: 0.0910 SGD.
What is the quality score of P8A?
CORDLIFE GROUP LIMITED has a Quality Score of 47/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for CORDLIFE GROUP LIMITED (P8A)?
Our calculated price target is the estimate of 0.1067 SGD (as of Nov 15, 2026). Cautious scenario 0.0821 SGD, optimistic scenario 0.1313 SGD. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the CORDLIFE GROUP LIMITED stock forecast for 2026?
Our estimate puts fair value at 0.1067 SGD, about +17% upside versus a price of 0.0910 SGD (fairly valued). Cautious scenario 0.0821 SGD, optimistic scenario 0.1313 SGD. The calculation is refreshed regularly with new filings.
What is the revenue of CORDLIFE GROUP LIMITED (P8A)?
CORDLIFE GROUP LIMITED reported trailing-twelve-month revenue of about 37.0M SGD (latest available figure, as of Nov 15, 2026).
Does CORDLIFE GROUP LIMITED pay a dividend?
CORDLIFE GROUP LIMITED currently shows a dividend yield of 0.31% relative to its recent price (as of Nov 15, 2026).
How much is the dividend of CORDLIFE GROUP LIMITED (P8A)?
CORDLIFE GROUP LIMITED has a dividend yield of 0.3%.
What is the intrinsic value of CORDLIFE GROUP LIMITED (P8A)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For CORDLIFE GROUP LIMITED it is 0.1067 SGD per share (as of Nov 15, 2026), against a price of 0.0910 SGD.
Is CORDLIFE GROUP LIMITED stock overvalued or undervalued in 2026?
As of Nov 15, 2026, P8A trades below its calculated fair value: price 0.0910 SGD, fair value 0.1067 SGD, a gap of about +17% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of P8A?
No. The price is what the market pays today (0.0910 SGD); the fair value is what the company's own numbers justify (0.1067 SGD). For CORDLIFE GROUP LIMITED the two are 0.0157 SGD per share apart. That gap is exactly why we show both numbers side by side.
How much is CORDLIFE GROUP LIMITED worth?
The market values CORDLIFE GROUP LIMITED at about 23.3M SGD (market capitalisation, as of Nov 15, 2026). Per share that is 0.0910 SGD; our models calculate a fair value of 0.1067 SGD per share.
What do the bullish and bearish scenarios say about P8A?
Our models span a range for CORDLIFE GROUP LIMITED: cautious scenario 0.0821 SGD, base 0.1067 SGD, optimistic 0.1313 SGD per share (as of Nov 15, 2026, price 0.0910 SGD). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of CORDLIFE GROUP LIMITED (P8A)?
Balance-sheet figures for CORDLIFE GROUP LIMITED (as of Nov 15, 2026): return on equity −10.1%. They feed the Quality Score of 47/100, which measures business quality independently of the share price.
How far is P8A from its 52-week high?
CORDLIFE GROUP LIMITED trades at 0.0910 SGD, about 52% below its 52-week high of 0.1900 SGD and at the low of 0.0910 SGD (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of 0.1067 SGD is for.
Which stocks are comparable to CORDLIFE GROUP LIMITED?
From the same area (Healthcare) we also value Thermo Fisher Scientific Inc, Danaher Corporation, WuXi AppTec Co, IDEXX Laboratories, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is CORDLIFE GROUP LIMITED stock attractive at the current price?
The data as of Nov 15, 2026: price 0.0910 SGD, calculated fair value 0.1067 SGD (+17%), Quality Score 47/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5% above its aggregate fair value. CORDLIFE GROUP LIMITED currently trades 15% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of CORDLIFE GROUP LIMITED (P8A)?
The closing price on Nov 10, 2026 was 0.0910 SGD. Our estimate is 0.1067 SGD, about +17% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with CORDLIFE GROUP LIMITED right now?
Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual. The price sits in the lower half of our model range, the side with the larger margin of safety. Read the verdict with care: some models are missing inputs, so the estimate scatters more than usual.

Key figures of CORDLIFE GROUP LIMITED

How large is the market capitalisation of CORDLIFE GROUP LIMITED (P8A)?
The market capitalisation of CORDLIFE GROUP LIMITED is 23.3M SGD (≈ $18.1M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of CORDLIFE GROUP LIMITED (P8A)?
The price-to-sales ratio of CORDLIFE GROUP LIMITED is 0.64 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of CORDLIFE GROUP LIMITED (P8A)?
Earnings per share at CORDLIFE GROUP LIMITED are −0.0400 SGD. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of CORDLIFE GROUP LIMITED (P8A)?
The dividend yield of CORDLIFE GROUP LIMITED is 0.3%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of CORDLIFE GROUP LIMITED (P8A)?
The net margin of CORDLIFE GROUP LIMITED is −28.9% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of CORDLIFE GROUP LIMITED (P8A)?
The return on equity (ROE) of CORDLIFE GROUP LIMITED is −10.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of CORDLIFE GROUP LIMITED (P8A)?
On an EBIT basis the return on assets of CORDLIFE GROUP LIMITED is −3.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of CORDLIFE GROUP LIMITED (P8A)?
The operating margin of CORDLIFE GROUP LIMITED is −18.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at CORDLIFE GROUP LIMITED (P8A)?
Revenue at CORDLIFE GROUP LIMITED is down 13.6% versus a year earlier (3y avg −11.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at CORDLIFE GROUP LIMITED (P8A)?
Earnings per share at CORDLIFE GROUP LIMITED are down 57.3% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does CORDLIFE GROUP LIMITED (P8A) generate?
The free cash flow of CORDLIFE GROUP LIMITED is −1.4M SGD (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
Free · no account needed

Watch CORDLIFE GROUP LIMITED in the live analysis

One click puts CORDLIFE GROUP LIMITED on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.